Published in Cancer Res on July 15, 2004
The pharmacology of sigma-1 receptors. Pharmacol Ther (2009) 3.12
The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci (2010) 2.11
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer (2007) 1.46
MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem (2012) 1.43
Mitochondrial Ca(2+) and apoptosis. Cell Calcium (2012) 1.36
Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: constitutive enhancement of calcium signaling in MCF-7 tumor cells. J Biol Chem (2008) 1.32
Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. Int Rev Cell Mol Biol (2013) 1.23
Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli. Protein Expr Purif (2006) 1.22
NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia (2009) 1.22
Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol Pharmacol (2010) 1.15
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer (2010) 0.93
Haloperidol induces the nuclear translocation of phosphatidylinositol 3'-kinase to disrupt Akt phosphorylation in PC12 cells. J Psychiatry Neurosci (2007) 0.92
The sigma-1 receptor binds to the Nav1.5 voltage-gated Na+ channel with 4-fold symmetry. J Biol Chem (2012) 0.92
Sig1R protein regulates hERG channel expression through a post-translational mechanism in leukemic cells. J Biol Chem (2011) 0.91
Proenkephalin assists stress-activated apoptosis through transcriptional repression of NF-kappaB- and p53-regulated gene targets. Cell Death Differ (2007) 0.89
Protective effects of the sigma agonist Pre-084 in the rat retina. Br J Ophthalmol (2007) 0.89
Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors. J Med Chem (2011) 0.88
Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse (2012) 0.88
Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells. Mol Vis (2010) 0.87
Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis (2013) 0.85
The sigma-1 receptor: a regulator of cancer cell electrical plasticity? Front Physiol (2013) 0.84
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol (2013) 0.84
Neuroprotective effects of high affinity Σ1 receptor selective compounds. Brain Res (2011) 0.83
Cholesterol at the endoplasmic reticulum: roles of the sigma-1 receptor chaperone and implications thereof in human diseases. Subcell Biochem (2010) 0.83
Characterization of interactions of 4-nitrophenylpropyl-N-alkylamine with ς receptors. Biochemistry (2011) 0.81
Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors. Bioorg Med Chem (2010) 0.81
AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma. Oncotarget (2015) 0.80
A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®). J Biol Chem (2014) 0.80
Inhibition of tumor cell growth by Sigma1 ligand mediated translational repression. Biochem Biophys Res Commun (2012) 0.80
Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma. J Histochem Cytochem (2012) 0.80
Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro. Eur J Pharmacol (2013) 0.79
Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor. Br J Pharmacol (2011) 0.79
Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress. Mol Pharmacol (2013) 0.79
Neuroactive steroids protect retinal pigment epithelium against oxidative stress. Neuroreport (2005) 0.77
Sigma1 receptors inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 to Orai1. J Cell Biol (2016) 0.76
Development and evaluation of a novel radioiodinated vesamicol analog as a sigma receptor imaging agent. EJNMMI Res (2012) 0.75
Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists. Neoplasia (2007) 0.75
Isolation and characterization of alternatively spliced variants of the mouse sigma1 receptor gene, Sigmar1. PLoS One (2017) 0.75
Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases. J Biomed Sci (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature (2008) 18.84
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol (2011) 10.40
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
Five-vertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding. Science (2010) 7.41
Transient receptor potential cation channels in disease. Physiol Rev (2007) 6.91
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res (2004) 5.24
The evolutionary landscape of alternative splicing in vertebrate species. Science (2012) 4.78
Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci (2005) 4.07
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J (2003) 3.77
Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J (2003) 3.58
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A (2004) 3.21
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science (2004) 3.08
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J Cell Biol (2002) 3.05
The Concise Guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol (2013) 3.03
Essential role of PDK1 in regulating cell size and development in mice. EMBO J (2002) 2.93
Molecular mechanisms of kinetochore capture by spindle microtubules. Nature (2005) 2.90
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res (2008) 2.76
Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet (2003) 2.73
A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med (2002) 2.68
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature (2003) 2.47
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
PTEN: The down side of PI 3-kinase signalling. Cell Signal (2002) 2.34
dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat Cell Biol (2002) 2.31
A network of multiple regulatory layers shapes gene expression in fission yeast. Mol Cell (2007) 2.29
How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov (2007) 2.29
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells (2008) 2.20
Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of phospholipase C delta1. Biochem J (2002) 2.16
The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J (2004) 2.11
The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol (2013) 2.07
A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res (2010) 2.05
Rapid turnover of long noncoding RNAs and the evolution of gene expression. PLoS Genet (2012) 2.05
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem (2010) 2.04
Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics. J Neurosci (2005) 2.03
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00
Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. J Theor Biol (2012) 2.00
Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. J Neurosci (2003) 1.97
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle (2009) 1.96
A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci U S A (2005) 1.94
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol (2013) 1.88
The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J (2004) 1.87
The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology (2002) 1.85
Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J (2002) 1.83
The delta subunit of gamma-aminobutyric acid type A receptors does not confer sensitivity to low concentrations of ethanol. J Pharmacol Exp Ther (2005) 1.82
Inhibition of autophagy in mitotic animal cells. Traffic (2002) 1.81
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell (2012) 1.81
Neurosteroid modulation of GABAA receptors. Prog Neurobiol (2003) 1.80
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer (2011) 1.79
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res (2005) 1.78
Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J (2004) 1.77
Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol (2008) 1.73
A coordinated global control over cellular transcription. Curr Biol (2010) 1.72
Multiple pathways differentially regulate global oxidative stress responses in fission yeast. Mol Biol Cell (2007) 1.72
Cyclin D1 and breast cancer. Breast (2006) 1.71
The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol (2013) 1.70
The 5-HT3 receptor--the relationship between structure and function. Neuropharmacology (2008) 1.70
Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol (2006) 1.68
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem (2007) 1.67
IUPHAR-DB: updated database content and new features. Nucleic Acids Res (2012) 1.66
Analysis of the LKB1-STRAD-MO25 complex. J Cell Sci (2004) 1.65
PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol (2007) 1.62
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res (2011) 1.61
Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J (2003) 1.59
Cohesin regulates tissue-specific expression by stabilizing highly occupied cis-regulatory modules. Genome Res (2012) 1.58
Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther (2007) 1.56
Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem (2008) 1.55
Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and -independent pathways. J Cell Sci (2011) 1.55
Neurosteroids: endogenous allosteric modulators of GABA(A) receptors. Psychoneuroendocrinology (2009) 1.52
TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J Cell Sci (2008) 1.52
In-patient treatment of opiate dependence: medium-term follow-up outcomes. Br J Psychiatry (2005) 1.47
14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. J Cell Sci (2005) 1.46